Pharmac consultation: proposal on access criteria for two COVID-19 treatments

on 21 February

Kia ora
Please follow this link to the Pharmac Consultation regarding proposed access criteria for nirmatrelvir with ritonavir (Paxlovid, Pfizer PF-07321332) and molnupiravir (Lageviro, MK-4482) for the treatment of COVID-19.
Pharmac welcomes feedback on this proposal.

To provide feedback, please email by 5pm on Wednesday 2nd March 2022.
Please circulate this email to others who may be interested.
Ngā mihi nui

Ben Graham | Therapeutic Group Manager
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

Back to blog entries

Areas of Interest